Proniras Corp Stock

Proniras Corp focuses on development of a new parenteral medical countermeasure (MCM) to treat seizures and brain injury.

Sign up today and learn more about Proniras Corp Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Proniras Corp Stock

Proniras Corp is an operator of a biomedical company intended to develop drugs. The company's biomedical service has already demonstrated preclinical efficacy in treating nerve agent-induced seizures, as well as in studies of rodents exposed to the chemical weapon soman, which is more toxic than sarin gas, enabling medical researchers to continue their research work and discover drugs. It was founded in 2016 and is headquartered in Seattle, Washington.

Funding History

August 2017$4.3M
July 2019$4.3M
February 2024$4.7M


Board Member

Steven Gillis

CEO & Director

Thong Le

Co-Founder and Chief Scientific Officer

Christopher Toombs

Board Member

Thong Le

Board Member

Atul Saran


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: